<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>6 Lymphoma</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part11.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part13.htm">Далее &gt;</a></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="#bookmark11" class="s17" name="bookmark43">Chapter 6</a><a name="bookmark44">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_071.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><h2 href="#bookmark11">Lymphoma</h2></p><p class="s18" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;line-height: 111%;text-align: left;">Heok Cheow, Peter Hoskin, and thankamma ajithkumar</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-top: 12pt;padding-left: 11pt;text-indent: 0pt;text-align: justify;">6.1 <span class="h4">Introduction</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Lymphoma covers a broad spectrum of disease entities which is reflected in a wide range of imaging involved in its diagnosis and management. It can be unifocal or multifocal, affecting lymph nodes or other organs. The two main groups, namely Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), have very different patterns of disease distribution which can influence imaging strategies; however, the pathological subtypes, whilst important in disease management, do not greatly influ- ence the staging processes for which imaging is used.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Contrast-enhanced computed tomography (CT) has a central role in the diagnosis, staging, and follow-up of lymphoma. In addition, extra nodal lymphoma is common, seen in approximately 40% of NHL, and these sites may have specific imaging require- ments. However, lymphoma is one of the first conditions where molecular imaging with positron emission tomography/computed tomography (PET/CT), using <span class="s22">18</span>F- fluorodeoxyglucose (<span class="s22">18</span>F-FDG) as the tracer, has been incorporated in international criteria for response.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The most common feature of lymphoma is lymph node enlargement. The central role of diagnostic imaging is therefore to identify pathological lymph nodes and distinguish these from normal nodes which can be enlarged due to physiological re- active change. The anatomical cross-sectional imaging modalities of computed tom- ography (CT), ultrasound (US), and magnetic resonance imaging (MRI) examine nodal architecture, whereas molecular imaging with <span class="s22">18</span>F-FDG PET/CT demonstrates alteration in physiology following neoplastic invasion. Both anatomical and mo- lecular imaging techniques require a substantial degree of nodal involvement before a convincing abnormality can be identified; in early disease, imaging may be falsely negative.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">Normal nodes are ovoid in morphology with a long-short axis ratio of around 1.5–</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">2.1. They have a fatty hilum, smooth cortex, and well-defined margins. When a node becomes involved in a neoplastic process such as lymphoma, it enlarges, particularly in the short axis, resulting in a more rounded contour, and a reduction in the long- short axis ratio. The cortex may become irregular and there can be loss of the fatty hilum as neoplastic displaces normal nodal tissue. The margin of the cortex may be breached, which results in poor definition of the nodal margins on imaging.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="188" alt="image" src="Image_072.jpg"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 6.1 <span class="s25">Illustration of a normal lymph node: the lymph node has ovoid morphology with smooth cortex shown in grey and central hilar fat in white (arrow). the minimum short axis diameter (a) is measured at the widest point of the node, at 90˚ to the long axis (b).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The minimum short-axis diameter is the standard measurement criteria in lymph node for most malignancies. This is the minimum diameter of the node when meas- ured at its widest point along the short axis, taken at 90° to the long axis (Figure 6.1). Nodes which measure &gt;1 cm in minimum short-axis diameter are generally con- sidered likely to be involved in a neoplastic process, with a sensitivity and specificity of 70%. The long-axis measurement is generally not as good an indicator for presence of disease as normal nodes may be long and slender. By consensus, the International Working Group for Lymphoma has, in 2007, defined an abnormal lymph node as</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">&gt;1.0 cm in short axis and &gt;1.5 cm in long axis diameter. These criteria are still used in many international lymphoma trials.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">6.2 <span class="h4">Diagnosis and investigations</span></p><p class="s28" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.2.1 <span class="s29">Diagnosis</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">HL and NHL have different patterns of disease spread and distribution; these deter- mine the imaging modalities which are most frequently involved in making the first step towards the diagnosis. Lymphoma is the great clinical and radiological pretender and frequently mimics other aggressive conditions, such as solid neoplasms, infec- tion, and sarcoid. It is only after biopsy and pathological assessment that a confident diagnosis can be established. Imaging is frequently used to guide core biopsy to obtain tissue for pathological diagnosis in non-palpable cases.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">HL spreads via the lymphatics, resulting in a disease distribution which is contiguous along lymphatic pathways. It is more common above the diaphragm and generally involves lymph nodes within the mediastinal (70%), cervical (70%) and paraaortic (30%) groups, and the spleen (30%). Patients may present with respiratory symptoms or B symptoms which prompt a chest X-ray as part of baseline investigations, which may demonstrate mediastinal lymphadenopathy (Figure 6.2). Alternatively, cervical lymphadenopathy will result in referral to a head and neck surgeon who may request</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 102pt;text-indent: 0pt;text-align: left;"><span><img width="186" height="212" alt="image" src="Image_073.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 6.2 <span class="s25">Hodgkin lymphoma: chest x-ray showing mediastinal lymphadenopathy.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">US and/or MRI to establish the origin of the palpable mass. US and MRI are particu- larly useful imaging modalities for the definition of neck anatomy; they have higher tissue contrast than CT and do not suffer from beam-hardening artefact due to dental amalgam which frequently degrades images of the upper neck.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">NHL consists of a spectrum including B and T cell lymphoma which have their distinct characteristics. NHL can undergo haematological spread, resulting in a more diverse and discontinuous pattern of disease distribution than HL. It is commonly found on both sides of the diaphragm, with para-aortic (50%), mesenteric (50%), and mediastinal (30%) lymphadenopathy. There is also a high propensity for extra-nodal disease compared to HL, including bone marrow (30%), bowel (10%), renal tract (7%), central nervous system (2%), and lung parenchyma (3%). This is reflected in the wider range of imaging techniques used for diagnosis, including MRI for marrow and neuro- logical lymphoma, and US for testicular lymphoma. Gastrointestinal mucosa associ- ated lymphoma (MALT) most commonly involving the stomach or large bowel can be indistinguishable on imaging from adenocarcinoma, with irregular thickening of the wall and shouldering at the interface with normal anatomy. Lymphomatous in- volvement of the bowel can be suggested by longer segment involvement and better preservation of lumen than is generally seen with carcinomas, and involvement of the terminal ileum is more frequent with lymphoma.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">Essential investigations for lymphoma would include the following:</p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Excision biopsy or core needle biopsy for histological diagnosis, including full immunohistochemical profile, flow cytometry, and cytogenetic analysis when necessary.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: justify;">◆ <span class="p">CT imaging from base of skull to femoral regions.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Peripheral blood count, erythrocyte sedimentation rate, serum lactate dehydro- genase (LDH), serum albumen, and markers of renal and hepatic function.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: justify;">◆ <span class="p">Immunoglobulin profile and protein electrophoresis.</span></p><p class="s23" style="padding-top: 4pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Bone marrow examination: no longer indicated for the routine staging of HL after PET/CT and most DLBCL. If there is uncertainty regarding bone marrow involve- ment in these situations or other lymphomas where involvement of bone marrow might alter treatment (e.g. early stage low-grade NHL), a bone marrow examin- ation is indicated.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;">◆ <span class="p">Cerebrospinal fluid in NHL patients with high-risk features, in particular lymphoma affecting the paranasal sinuses and testes.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s28" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">6.2.2 <span class="s29">Anatomical imaging</span></p><p class="s28" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.2.2.1 <span class="s66">Computed tomography</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">CT remains the mainstay of imaging for the staging of lymphoma. Modern helical multi-slice scanners now allow sub-millimetre imaging through the neck, chest, ab- domen, and pelvis to be obtained in seconds, with isotropic axial, coronal, and sagittal reconstructions producing high quality images. This has increased image interpret- ation accuracy, helped by the use of intravenous contrast medium, which allows confi- dent differentiation between lymph nodes and blood vessels. CT can accurately identify not only enlarged lymph nodes and categorize these by virtue of their size, shape, and numeracy, but can also demonstrate disease in extra nodal sites, for example the brain, lungs, gastrointestinal tract, kidneys, liver, and spleen. Other cross-sectional imaging modalities complement CT findings in particular anatomical regions and clarify le- sions which are indeterminate on CT.</p><p class="s28" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.2.2.2 <span class="s66">Ultrasound</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">US is useful in assessing indeterminate liver and renal lesions and has a role in imaging splenic lymphoma. The spleen has a high propensity for lymphomatous involvement, particularly in HL. Based on historical series where laparotomy and splenectomy were a routine component of treatment, up to one-third of normal sized spleens contain microscopic HL, whereas only approximately one-third of enlarged spleens were in- volved. Splenic size alone is therefore not helpful. US can detect splenic lesions down to 3 mm in diameter with higher sensitivity than CT for the detection of splenic lymphoma (63% vs. 37%). The disadvantage of the use of US in lymphoma staging lies in the fact that its performance is best when targeted to specific organs; and it is depth and operator dependent, making assessment of disease less reproducible than CT or MRI, especially in the therapy response setting.</p><p class="s28" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.2.2.3 <span class="s66">Magnetic resonance imaging</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">With recent advances in MRI technology, whole body MRI is now feasible, with the advantage of no radiation exposure (Figure 6.3). MRI has superior performance to CT in assessing lymph nodes when diffusion-weighted sequences are incorporated within the acquisition protocol, and also in assessing extranodal disease, especially in the as- sessment of the neural axis, bone marrow, head and neck, and pelvic regions. In bone marrow assessment, MRI enables global assessment of the disease distribution more accurately than single or paired bone marrow aspirates and trephine samples from the iliac crests, identifying bone marrow infiltration in up to 33% of patients who have</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="289" alt="image" src="Image_074.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 6.3a <span class="s25">Selected coronal t1-weighted turbo spine echo whole body mrI images showing normal marrow signal intensity.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="292" alt="image" src="Image_075.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 6.3b <span class="s25">Selected coronal t2-weighted whole body mrI images with StIr fat suppression showing normal marrow signal intensity.</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">negative iliac crest biopsies. False negatives may occur where there is only scanty infil- tration and in indolent lymphomas.</p><p class="s28" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.2.2.4 <span class="s66">Molecular imaging</span></p><p class="s65" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">18<span class="s44">F-FDG PET/CT has established itself as an invaluable tool in the management of lymphoma. The principles of </span>18<span class="s44">F-FDG PET/CT are described in Chapter 2. This imaging modality is now advocated as the main modality for staging FDG-avid dis- ease (Table 6.1) in the Lugano Classification 2014.</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In the evaluation of lymphoma, the sensitivity of <span class="s22">18</span>F-FDG PET/CT of 85–90% is 15% higher than with CT as PET/CT can identify elevated metabolic activity in normal- sized lymph nodes (Figure 6.4). PET/CT can also detect focal or multi-focal bone marrow involvement where an iliac crest sample is negative (Figure 6.5). Because of this, bone marrow biopsy can be omitted for the routine staging of Hodgkin lymphoma and diffuse large B cell lymphoma (DLBCL). Specificity for CT and PET/CT are equiva- lent at 70% for lymphomatous involvement. False positive results can result from FDG uptake by granulomatous disorders such as sarcoid and infection (particularly TB), physiological brown fat, muscle, tonsils, and bowel activity. Uptake can also be seen in inflammatory and degenerative arthritis.</p><p class="s65" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">18<span class="s44">F-FDG PET/CT is less useful in defining involvement with indolent lymphoma as it</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">is not possible differentiate involved nodes from benign, reactive nodes. Nevertheless, FDG PET/CT may have a role in identifying transformation to high-grade disease. Several studies have found PET/CT may identify potential sites of transformation, in- dicated by elevated metabolic activity, in nodes or organs which can be targeted for biopsy.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Table 6.1 <span class="s25">fdG avidity according to different lymphoma subtypes</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_076.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_077.png"/></span></p><p class="s39" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Lymphoma subtypes                 Percentage of FDG avidity</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_078.png"/></span></p><p class="s41" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Burkitt lymphoma                    100</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_079.png"/></span></p><p class="s41" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">mantle cell lymphoma                  100</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_080.png"/></span></p><p class="s41" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Hodgkin lymphoma                   97–100</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_081.png"/></span></p><p class="s41" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">diffuse large B cell lymphoma               97–100</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_082.png"/></span></p><p class="s41" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">anaplastic large t-cell lymphoma             94–100</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_083.png"/></span></p><p class="s41" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">follicular lymphoma                   91–100</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_084.png"/></span></p><p class="s41" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">natural killer/t cell lymphoma               83–100</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_085.png"/></span></p><p class="s41" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">angioimmunoblastic t cell lymphoma         78–100</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_086.png"/></span></p><p class="s41" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Peripheral t cell lymphoma               86–98</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_087.png"/></span></p><p class="s41" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">mucosa-associated lymphoid tissue (malt) lymphoma   54–81</p><p class="s41" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Small lymphocytic lymphoma               47–83</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_088.png"/></span></p><p class="s21" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 111%;text-align: left;">Source: data from Barrington Sf, mikhaeel n, Kostakoglu l, et al. ‘role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group’. <i>J Clin Oncol </i>2014, 32(27), pp.3048–3058.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 16pt;text-indent: 0pt;text-align: left;"><span><img width="409" height="285" alt="image" src="Image_089.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 6.4 <span class="s81">18</span><span class="s82">f-fdG Pet/Ct showing areas of increased fdG uptake despite normal left common iliac node on size criteria.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 16pt;text-indent: 0pt;text-align: left;"><span><img width="409" height="385" alt="image" src="Image_090.jpg"/></span></p><p class="s24" style="padding-top: 8pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 6.5 <span class="s81">18</span><span class="s82">f-fdG Pet/Ct showing bone marrow involvement with lymphoma.</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In general, management of both types of lymphoma will depend upon stage, with patients classified into early or advanced disease. Those with early disease, that is stage Ia or IIa, will be treated with short-course chemotherapy and involved node (site) radiotherapy (see below) whilst those with more aggressive disease, that is patients with stage Ib, IIb, III, or IV, will receive more prolonged combination chemotherapy.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A change in stage therefore will only be relevant to treatment if a patient without B symptoms is moved from stage I or II to stage III or IV. With the high sensitivity of <span class="s22">18</span>F-FDG PET/CT in identifying additional sites, that is, stage III or IV disease, this typically does not alter management. Similarly, where additional sites in one anatom- ical region are identified, the added information from PET/CT will not alter overall management although it might be important in determining radiotherapy volume. In current clinical practice, the baseline PET/CT is compared with an interim imaging (usually done after two cycles of chemotherapy) to assess for an early metabolic re- sponse. Evidence suggests that in HL an early response on molecular imaging, in par- ticular PET/CT, predicts outcome and guides further treatment modifications (see below).</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.2.3 <span class="s29">Staging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The aim of staging is to identify the full extent of disease prior to treatment, in order to define the best treatment. Currently <span class="s22">18</span>F-FDG PET/CT is routinely recommended for staging all FDG-avid nodal lymphomas. In FDG non-avid histological subtypes such as CLL/small lymphocytic lymphoma, lymphoplasmacytic lymphoma/Walderstrom’s macroglobulinaemia, mycosis fungoides, and marginal zone lymphomas, CT scan is used for staging. The Lugano modification of Ann-Arbor staging can be viewed here:<span class="s22">1</span></p><p style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;"><span class="s23">◆ </span>B symptoms: fever (&gt;38.3<span class="s22">°</span>C), drenching night sweats, or weight loss &gt;10% body weight over six months. B symptoms only affect HL and therefore this qualifier is only used for HL.</p><p style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: justify;"><span class="s23">◆ </span>Splenic involvement is defined as diffuse uptake, solitary mass, military lesions or nodules on <span class="s22">18</span>F-FDG PET/CT or splenomegaly is defined as &gt;13 cm in vertical length on CT scan, if FDG non-avid.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">6.3 <span class="h4">Radiotherapy planning</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The role of radiotherapy in the management of lymphoma has changed substantially with the advent of effective combination chemotherapy. It is, however, still the most active single modality in the management of lymphoma, and in HL radiotherapy remains an important component of treatment regimens, particularly in early dis- ease. Similarly, in early stage NHL, radiotherapy remains an important addition to short-course chemotherapy in standard management. There have also been substan- tial changes in radiotherapy equipment and techniques in the last decade. Routine use of <span class="s22">18</span>F-FDG PET/CT in staging has led to the replacement of involved-field radio- therapy (IFRT: treating the anatomical nodal region involved at diagnosis) with involved-node radiotherapy (INRT: treating a target volume of radiotherapy com- prising pre-chemotherapy nodal disease only) (Figure 6.6). However, a pre-requisite</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="414" height="112" alt="image" src="Image_091.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;">Fig. 6.6 <span class="s25">an illustration of evolution of treatment volumes in lymphoma: (a) involved-field radiotherapy; (b) involved-node radiotherapy; and (c) involved-site radiotherapy.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">for INRT is imaging with <span class="s22">18</span>F-FDG PET/CT at diagnosis and after chemotherapy in the radiotherapy treatment position and with the same breathing instructions. Since the majority of clinical departments cannot obtain diagnostic PET/CT in radiotherapy treatment position, the current clinical practice is a modification of INRT technique called involved-site radiotherapy (ISRT). The CTV for ISRT comprises the pre- chemotherapy nodal disease with a margin of 15 mm to allow for uncertainties in the contouring. If diagnostic (pre-chemotherapy) PET/CT is not available, IFRT should be considered to avoid any risk of potential recurrences in the anatomical region.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">6.3.1 <span class="s29">CT</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: left;">CT based planning is the standard for all lymphoma. CT planning has numerous advantages, including:</p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">More accurate definition of lymph node areas.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">More accurate definition of extra nodal sites.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">More accurate definition of organs at risk (OAR).</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Incorporation of tissue inhomogeneities within the planning algorithm for more accurate dose distributions.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Dose volume histogram analyses for coverage of planning target volume (PTV) and OAR.</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Planning CT scan is generally obtained with a slice thickness of 2–3 mm. Intravenous contrast aids identification of the lymph node chains and differentiates nodes from blood vessels. Contrast has no substantial effect upon the dosimetry algorithms for radiotherapy planning. For abdominal and pelvic nodes, oral contrast is useful to delineate intestinal loops. 4D CT imaging may be considered for sites that change with respiration and close to the heart (which may move with respiration and cardiac cycle). Definition of the clinical target volume (CTV) is based on the known lymph node area to be covered using standard published lymph node atlases. OARs should also be outlined in this process, as shown in Figure 6.7.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">6.3.2 <span class="s29">PET and MRI</span></p><p class="s65" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: left;">18<span class="s44">F-FDG PET uptake is required to identify actual sites of involvement with lymphoma distinct from lymph node regions when using the concepts of INRT and ISRT. The CTV</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="267" alt="image" src="Image_092.jpg"/></span></p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(e)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s62" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(f)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: justify;">Fig. 6.7 <span class="s25">diagnostic Pet scan (a&amp;b) which is co-registered with planning Ct images (c–e) in a patient with Hodgkin lymphoma. Coronal planning Ct imaging showing oars (c) and clinical target volume (CtV) for involved-site radiotherapy (d&amp;e).</span></p><p class="s25" style="padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: justify;">note: CtV is modified based on post-chemotherapy anatomical changes. (e) treatment planning using Imrt.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">for INRT is defined as the initially involved lymph nodes on the pre-chemotherapy PET/CT, obtained in the treatment position, which is then modified based on post- chemotherapy anatomical changes (Figure 6.7). MRI is useful for radiotherapy plan- ning for lymphomas in the central nervous system, paranasal sinuses, orbit, and musculoskeletal system as MRI provides a greater soft tissue contrast compared to CT.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s19" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">6.4 <span class="h4">Therapeutic response and follow-up</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">As there are various chemotherapy regimens available for treatment, the aim for HL and aggressive NHL is to achieve cure, whereas for low-grade indolent lymphoma, disease control and prolonged survival is often the goal. Imaging plays a pivotal role in selecting treatment regime and assessment of disease response. Contrast enhanced CT is used for indolent lymphoma and PET/CT for FDG-avid lymphoma.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The imaging modality of choice for assessing therapy response will be tailored depending on the distribution of disease at staging. However, if initial staging revealed disease in a region which required another modality for full assessment (e.g. US for testicular, MRI for Waldeyer’s ring disease, brain, and bone marrow), then these mo- dalities will also be required for follow-up imaging.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Response can be defined as resolution or reduction in size of the enlarged lymph node or extranodal mass on anatomical imaging and reduced metabolic activity on <span class="s22">18</span>F-FDG PET/CT. A post therapy residual mass will cause uncertainty whether it represents residual active disease or post therapy fibrotic mass. PET/CT assesses</p><p class="s24" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Table 6.2 <span class="s25">deauville five-point scale</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:11.3381pt" cellspacing="0"><tr style="height:14pt"><td style="width:26pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Score</p></td><td style="width:118pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">FDG uptake based on SUVmax</p></td><td style="width:179pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Interpretation</p></td></tr><tr style="height:26pt"><td style="width:26pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">1</p></td><td style="width:118pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">no uptake</p></td><td style="width:179pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 112%;text-align: left;">Considered to represent complete metabolic response (Cmr) at interim and end of treatment</p></td></tr><tr style="height:26pt"><td style="width:26pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">2</p></td><td style="width:118pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">≤ mediastinal blood pool</p></td><td style="width:179pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 112%;text-align: left;">Considered to represent complete metabolic response (Cmr) at interim and end of treatment</p></td></tr><tr style="height:33pt"><td style="width:26pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">3</p></td><td style="width:118pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 5pt;padding-right: 18pt;text-indent: 0pt;line-height: 112%;text-align: left;">&gt; mediastinal blood pool and ≤ liver</p></td><td style="width:179pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9"><p class="s27" style="padding-top: 2pt;padding-left: 10pt;padding-right: 4pt;text-indent: -5pt;line-height: 112%;text-align: left;">dependent on the timing of assessment, the clinical context and the treatment</p><p class="s27" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">fdG uptake declines during therapy in</p></td></tr></table><p class="s41" style="padding-bottom: 1pt;padding-left: 165pt;text-indent: 0pt;line-height: 112%;text-align: justify;">chemosensitive disease and residual fdG uptake higher than normal liver uptake is frequently seen at interim in patients who achieve Cmr at the end of treatment</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_093.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: justify;">4    moderately &gt; liver at any site   Suggests chemosensitive disease provided uptake</p><p class="s41" style="padding-top: 1pt;padding-left: 165pt;text-indent: 0pt;line-height: 112%;text-align: left;">has reduced from baseline and is considered to represent partial metabolic response at interim study</p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_094.png"/></span></p><p class="s41" style="padding-left: 165pt;text-indent: -5pt;line-height: 112%;text-align: left;">represents residual metabolic active disease even if the uptake has reduced from baseline at end of treatment</p><p class="s41" style="padding-top: 4pt;padding-left: 42pt;text-indent: -31pt;line-height: 112%;text-align: left;">5    markedly* &gt; liver at any site and/or new sites of disease</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_095.png"/></span></p><p class="s41" style="padding-left: 42pt;text-indent: -31pt;line-height: 112%;text-align: left;">X   new areas of uptake unlikely to be related to lymphoma</p><p class="s41" style="padding-top: 4pt;padding-left: 12pt;text-indent: -5pt;line-height: 112%;text-align: left;">Suggests chemosensitive disease provided uptake has reduced significantly from baseline and</p><p class="s41" style="padding-left: 12pt;text-indent: 0pt;line-height: 112%;text-align: left;">is considered to represent partial metabolic response at interim study</p><p class="s41" style="padding-left: 12pt;text-indent: -5pt;line-height: 112%;text-align: left;">represents residual metabolic active disease even if the uptake has reduced from baseline at end of treatment</p><p class="s41" style="padding-left: 12pt;text-indent: -5pt;line-height: 112%;text-align: left;">new sites of disease could represent disease progression, biopsy recommended.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_096.png"/></span></p><p class="s21" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">SuVmax: maximum standardized uptake value; * SuVmax of the lesion &gt;2x liver uptake</p><p class="s21" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 111%;text-align: left;">the response evaluation criteria for lymphoma has been published by the International Working Group (reCIl 2017) as shown below:</p><p class="s21" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 111%;text-align: left;">Source: data from Barrington Sf, mikhaeel n, Kostakoglu l, et al. role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J. Clin. oncol 2014, 32 (27), pp. 3048–3058.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">the metabolic activity with such mass. An international five-point scoring system (Deauville score) has been developed to give a guidance on residual mass based on its metabolic activity using two reference points of mediastinal blood pool and liver (Table 6.2).</p><p class="s1" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: justify;">Complete response:</p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">◆ <span class="p">Complete disappearance of all target lesions and all nodes with long axis</span></p><p style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">&lt;10 mm.</p><p style="padding-top: 4pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;"><span class="s23">◆ </span>≥30 decrease in the sum of longest diameters of target lesions with normalization of <span class="s22">18</span>F-FDG-PET/CT (Deauville 1–3).</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Bone marrow is not involved and no new lesion.</span></p><p class="s1" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Partial response:</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">◆ <span class="p">≥30% decrease in the sum of longest diameters of target lesions with positive</span></p><p class="s65" style="padding-left: 17pt;text-indent: 0pt;line-height: 12pt;text-align: left;">18<span class="s44">F-FDG-PET/CT (Deauville score 4–5).</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Bone marrow can be involved, but no new lesion.</span></p><p class="s1" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Minor response:</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">≥10% decrease but &lt;30% in the sum of longest diameters of target lesions.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="s65">18</span><span class="s44">F-FDG-PET/CT could be any Deauville score.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Bone marrow can be involved, but no new lesion.</span></p><p class="s1" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Stable disease:</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">&lt;10% decrease or ≤20% increase in the sum of longest diameters of target lesions.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="s65">18</span><span class="s44">F-FDG-PET/CT could be any Deauville score.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Bone marrow can be involved, but no new lesion.</span></p><p class="s1" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Progressive disease:</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">≥20% increase in the sum of longest diameters of target lesions.</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">For small lymph nodes measuring &lt;15 mm post therapy, a minimum absolute in- crease of 5 mm and the long diameter should exceed 15 mm.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Appearance of new lesion(s).</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="s65">18</span><span class="s44">F-FDG-PET/CT could be any Deauville score.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Bone marrow can be involved.</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">It has been shown that based on the above criteria, a selection of three as opposed to six largest target lesions at baseline for analysis did not jeopardize the final out- come. Target lesions should be lesions from disparate regions of the body, if possible, including mediastinal and retroperitoneal lesions whenever these sites are involved. Where uncertainty remains, then biopsy may be required to give a definitive answer.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.4.1 <span class="s29">Timing of imaging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Conventionally imaging will be timed to identify response during treatment, define the final response, and to monitor disease in follow-up. This will usually mean investi- gations at the following points:</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">During chemotherapy, typically after 2–4 cycles of treatment.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">At completion of chemotherapy.</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">At 3–6 months after completion of chemotherapy.</span></p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.4.2 <span class="s29">Interim PET/CT</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">There is emerging data to suggest that an early response on <span class="s22">18</span>F-FDG PET/CT in both HL and aggressive NHL after two cycles of chemotherapy is a strong predictor</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">of subsequent favourable outcome; those patients with negative scans at this point achieving conventional complete remissions and long-term, relapse-free survival times (Figure 6.8a &amp; b), whereas patients with a positive scan at this point are less likely to achieve complete remission and will subsequently progress. The role of an</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="260" alt="image" src="Image_097.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s25" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;"><span class="s24">Fig. 6.8a </span>Staging <span class="s63">18</span>f-fdG Pet/Ct of a stage IV dlBCl patient.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="416" height="286" alt="image" src="Image_098.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s25" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 117%;text-align: left;"><span class="s24">Fig. 6.8b </span>Interim <span class="s63">18</span>f-fdG Pet/Ct showing complete response following two cycles of r- CHoP chemotherapy.</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">interim PET/CT is to identify poor responders at an early stage, hence prevent futile chemotherapy, and prompt to change to more intensive treatment and also to min- imize further treatment to those who are in complete remission at this early stage. This interim study should be done just before the third cycle of chemotherapy.</p><p class="s28" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">6.4.3 <span class="s29">PET/CT at completion of treatment</span></p><p class="s65" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">18<span class="s44">F-FDG PET/CT at completion of treatment is an important prognostic indicator. Patients with a negative PET/CT scan at completion of treatment have a short-term progression-free survival of &gt;90%. The predictive value of a positive PET/CT scan at this point, however, is less certain, with a wide range of published figures reflecting the difficulties in interpretation early post-treatment. To avoid these false positive find- ings, it is recommended that at least six weeks are allowed after completion of all treat- ment before a definitive completion PET/CT scan is performed. A positive scan in these circumstances has been associated with only a 40% one-year progression-free survival compared to 95% for a contemporary PET/CT negative group. Interpretation of the PET/CT positive scan can be enhanced by reference to a staging PET/CT scan. Criteria for response have been defined by the International Harmonization Project (IHP) as shown in Table 6.3.</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In certain situations, <span class="s22">18</span>F-FDG PET/CT can be falsely positive, for example FDG can be taken up in thymic rebound following chemotherapy, in infection, in extra- medullary haematopoiesis, and in tissues undergoing inflammatory response to</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 5pt;text-indent: 0pt;line-height: 117%;text-align: left;">Table 6.3 <span class="s25">International Harmonization Project (IHP) consensus recommendations with inclusion of Pet criteria in defining response in lymphoma</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_099.png"/></span></p><p class="s41" style="padding-bottom: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">the following changes on <span class="s42">18</span>f-fdG Pet/Ct should be regarded as positive for lymphoma:</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_100.png"/></span></p><p class="s39" style="padding-top: 1pt;padding-bottom: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Lymph nodes:</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_101.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">≥2 cm diameter    diffuse or focal uptake &gt; mediastinal blood pool structures</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_102.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">&lt;2 cm diameter    any increase in uptake over background</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_103.png"/></span></p><p class="s39" style="padding-top: 1pt;padding-bottom: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Lung nodules:</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_104.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">&gt;1.5 cm diameter   Increase in uptake &gt; mediastinal blood pool structures</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_105.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">&lt;1.5 cm diameter   Cannot be reliably assessed</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_106.png"/></span></p><p class="s39" style="padding-top: 1pt;padding-bottom: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Hepatic and splenic lesions:</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_107.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">&gt;1.5 cm       uptake &gt; or = to normal liver or spleen</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_108.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">&lt;1.5 cm       uptake &gt; normal liver or spleen</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="433" height="1" alt="image" src="Image_109.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_110.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="431" height="1" alt="image" src="Image_111.png"/></span></p><p class="s41" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 164%;text-align: left;">diffuse splenic disease diffuse uptake &gt; normal liver (unless recent cytokine administration) Bone marrow     multifocal uptake</p><p class="s80" style="padding-bottom: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 112%;text-align: left;">Timing of scans after therapy: <span class="s41">6–8 weeks after chemotherapy or chemoimmunotherapy; 8–12 weeks after radiotherapy or chemoradiotherapy.</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="427" height="1" alt="image" src="Image_112.png"/></span></p><p class="s21" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 110%;text-align: left;">Source: data from Juweld me et al. ‘use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma’. <i>J Clin Oncol </i>2007; Vol. 25<span class="s94">, </span>Issue 5, pp.571–8.</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">radiation reaction. These foci of uptake can be misinterpreted as representing active lymphoma. An initial staging PET/CT image for comparison is valuable in this setting as foci of uptake which were not present on the staging scan are likely to be a conse- quence of treatment. Biopsy should be considered for any new lesion with high uptake on the interim or completion PET/CT, especially where salvage treatment is considered.</p><p class="s28" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">6.4.4 <span class="s29">Imaging in follow-up</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The role of routine imaging in the follow-up of lymphoma patients is controversial. On the one hand there is increasing concern with regard to the radiation exposure of patients who have a long prognosis, many living their natural lifespan from a rela- tively young age at treatment, being exposed to unnecessary irradiation. This must be balanced against the ability to detect early relapse enabling further potentially curative treatment. The predictive value of molecular imaging using <span class="s22">18</span>F-FDG PET/ CT therefore has considerable importance and interest in this area and the role of additional imaging in patients who are FDG negative at completion of treatment is questionable.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">There is no role for routine imaging beyond the initial post-treatment scan at 3–6 months after completion of therapy. Patients, who have residual disease, whether defined by CT criteria or positive disease on <span class="s22">18</span>F-FDG PET/CT scanning, clearly re- quire further monitoring. Where molecular imaging is not available then stable disease on two further CT scans at six-monthly intervals is adequate to justify discontinuation of further routine imaging, and where molecular imaging is available residual disease on a diagnostic CT scan followed by PET/CT which is negative, should also lead to the cessation of further routine imaging. A positive PET/CT scan should, in the absence of other criteria suggesting lymphoma relapse or progression, and be followed by a biopsy of the FDG-positive area.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Finally, the traditional annual chest X-ray no longer has a role in the management of lymphoma patients. The only role for routine radiology following treatment and confirmation of complete remission in lymphoma is in later screening programmes. Currently UK recommendations for female patients having had radiotherapy to chest area involving breast tissue before the age of 36 years are to begin MRI breast screening eight years after completion of treatment. In smokers an increased risk of lung cancer is recognized and studies are underway to identify the optimal means of monitoring such patients to identify early disease for those who persist in their smoking habits.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 11pt;text-indent: 0pt;text-align: justify;">Further reading</p><p class="s75" style="padding-top: 5pt;padding-left: 24pt;text-indent: -12pt;text-align: justify;">Cheson BD, Fisher RI, Barrington SF, et al. <span class="s74">(2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the</span></p><p class="s74" style="padding-left: 24pt;text-indent: 0pt;text-align: justify;">Lugano classification. <i>Journal of Clinical Oncology, </i><b>32</b>(27): 3059–3068. doi: 10.1200/ JCO.2013.54.8800.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -12pt;text-align: justify;"><b>Hoskin PJ</b>, <b>Díez P</b>, <b>Gallop-Evans E, et al. </b>(2016). Recommendations for radiotherapy technique and dose in extra-nodal lymphoma. <i>Clinical Oncology </i>(Royal College of Radiology), <b>28</b>(1): 62–68.</p><p class="s74" style="padding-top: 4pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Juweld ME</b>, <b>Stroobants S</b>, <b>Hoekstra OS, et al. </b>(2007). Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. <i>Journal of Clinical Oncology</i>,</p><p class="s75" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">25<span class="s74">: 571–578.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: justify;"><b>Mikhaeel NG</b>, <b>Milgrom SA</b>, <b>Terezakis S, et al. </b>(2019). The optimal use of imaging in radiation therapy for lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). <i>International Journal of Radiation and Oncology. Biology. Physics</i>,</p><p class="s75" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">104<span class="s74">(3): 501–512.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Specht L</b>, <b>Yahalom J</b>, <b>Illidge T, et al. </b>(2014). Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). <i>International Journal of Radiation and Oncology. Biology. Physics</i>,</p><p class="s75" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">89<span class="s74">(4): 854–862.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Yahalom J</b>, <b>Illidge T</b>, <b>Specht L, et al. </b>(2015). Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation and Oncology. Biology. Physics</i>, <b>1, 92</b>(1): 11–31.</p><p class="s74" style="padding-top: 1pt;padding-left: 18pt;text-indent: -12pt;text-align: left;"><b>Younes A</b>, <b>Hilden P</b>, <b>Coiffier B, et al. </b>(2017). International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i>, <b>28</b>(7): 1436–1447.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part11.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part13.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
